MedTrace Logo

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting

NCT07236814 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2026-03-23

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.

Conditions

Interventions

DRUG

Suraxavir marboxil

Suraxavir marboxil (40mg on the first day)

DRUG

Oseltamivir Placebo

Oseltamivir placebo(75mg each day during the first five days)

DRUG

Oseltamivir

Oseltamivir (75mg each day during the first five days)

DRUG

Suraxavir marboxil placebo

Suraxavir marboxil placebo (40mg on the first day).

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-28
Primary Completion
2027-03-01
Completion
2027-03-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07236814 on ClinicalTrials.gov